Drug Trial Radar · NCT06888193
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 5, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Mar 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
Conditions
- Moderate to Severe Plaque Psoriasis
- Psoriatic Arthritis
- Axial Spondyloarthritis
- Hidradenitis Suppurativa
Interventions
BimekizumabDrug
Bimekizumab under the care of their treating physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of bimekizumab in the breast milk on Day 1Time frame: Day 1
- Concentration of bimekizumab in the breast milk on Day 2Time frame: Day 2
- Concentration of bimekizumab in the breast milk on Day 3Time frame: Day 3
- Concentration of bimekizumab in the breast milk on Day 5Time frame: Day 5
- Concentration of bimekizumab in the breast milk on Day 7Time frame: Day 7
- Concentration of bimekizumab in the breast milk on Day 9Time frame: Day 9
- Concentration of bimekizumab in the breast milk on Day 11Time frame: Day 11
- Concentration of bimekizumab in the breast milk on Day 13Time frame: Day 13
- Concentration of bimekizumab in the breast milk on Day 15Time frame: Day 15
- Concentration of bimekizumab in the breast milk on Day 29Time frame: Day 29
- Concentration of bimekizumab in the breast milk on Day 57Time frame: Day 57
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Up0122 105
Santa Monica, California · Recruiting
Up0122 103
South Miami, Florida · Recruiting
Up0122 104
Boston, Massachusetts · Recruiting
Up0122 106
Chapel Hill, North Carolina · Recruiting
Up0122 102
Durham, North Carolina · Recruiting
Up0122 101
Milwaukee, Wisconsin · Recruiting
Up0122 202
Calgary, Canada · Recruiting
Up0122 201
Vancouver, Canada · Recruiting
Up0122 301
Freiburg im Breisgau, Germany · Recruiting
Up0122 303
Herne, Germany · Recruiting
Up0122 501
Barcelona, Spain · Recruiting
Up0122 502
Barcelona, Spain · Recruiting
Up0122 602
Lausanne, Switzerland · Recruiting
Up0122 601
Sankt Gallen, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.